Teun M. Post

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 19, 2025

Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia.

Model-Informed Drug Development for Daprodustat Supports the Design of Individualized Dosing Regimens in Chronic Kidney Disease Patients With Anemia.

Journal: Clinical pharmacology and therapeutics

Published: March 13, 2025

Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.

Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making.

Journal: CPT: pharmacometrics & systems pharmacology

Published: September 18, 2024

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development.

Journal: CPT: pharmacometrics & systems pharmacology

Published: September 18, 2024

Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.

Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.

Journal: Clinical pharmacokinetics

Published: August 15, 2024

Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease.

Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease.

Journal: Clinical pharmacology and therapeutics

Published: June 19, 2024

Building an adaptive dose simulation framework to aid dose and schedule selection.

Building an adaptive dose simulation framework to aid dose and schedule selection.

Journal: CPT: pharmacometrics & systems pharmacology

Published: May 22, 2023

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 27, 2023

Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.

Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.

Journal: Contraception

Published: August 30, 2022

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 31, 2022

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 01, 2020

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development.

Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 12, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026